Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by Onyx Pharmaceuticals
Lobbying Relationship
Bills mentioned
H.R.3204: Drug Quality and Security Act
Sponsor: Fred Upton (R-Mich.)
S.959: Pharmaceutical Quality, Security, and Accountability Act
Sponsor: Tom Harkin (D-Iowa)
H.R.1919: Safeguarding America's Pharmaceuticals Act of 2013
Sponsor: Robert E. Latta (R-Ohio)
S.957: Drug Supply Chain Security Act
Sponsor: Michael Bennet (D-Colo.)
S.3295: Departments of Labor, Health and Human Services, and Education, and...
Sponsor: Tom Harkin (D-Iowa)
H.R.4132: FAST Act
Sponsor: Cliff Stearns (R-Fla.)
S.2113: TREAT Act
Sponsor: Kay Hagan (D-N.C.)
H.R.2245: Preserving Access to Life-Saving Medications Act of 2011
Sponsor: Diana DeGette (D-Colo.)
S.296: Preserving Access to Life-Saving Medications Act
Sponsor: Amy Klobuchar (D-Minn.)
S.3187: Food and Drug Administration Safety and Innovation Act
Sponsor: Tom Harkin (D-Iowa)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Jennifer Leib | Policy Fellow, NIH/NHGRI Office of the Director |
| Nicholas G. Cavarocchi | n/a |
| Megan Anderson Brooks | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate